|
SolidMalignances
Head and Neck
• Phase II
o Drug class: EGRF MAB
o Patients enrolled: 150
• Phase III
o Drug class: EGRF MAB
o Patients enrolled: 400
Colorectal
• Phase II
o Drug Class: EGRF MAB
o Patients enrolled: 300
• Phase IV
o Drug class: platinum derivative
o Patients enrolled: 500
Renal
• Phase II
o Patients enrolled: 36
• Phase IIIb
o Drug Class: MKI
o Patients enrolled: 2,600
Breast
• Phase III
o Patients enrolled: 300
• Phase IIIb
o Drug class: TKI
o Patients enrolled: 1,100
Lung
• Phase III
o Patients enrolled: 200
• Phase III
o NSCLC (squamous and non squamous cell)
o Patients enrolled: 2,200
Prostate
• Phase III
o Drug Class: Platinum derivative
o Patients enrolled: 900
• Phase III
o Hormone refractory
o Patients enrolled: 940
Gastric
• Phase III
o Patients enrolled: 520
Exploratory Studies
• Phase I
o Lung
o AML
o Gastric
o Colorectal
|
HematologicMalignances
Acute Myeloid Leukemia
• Phase II
o First Line
o Patients enrolled: 120
• Phase II
o First Relapse
o Patients enrolled: 120
• Phase II
o First Line
o Patients enrolled: 75
• Phase III
o Patients enrolled: 350
• Phase III
o Vaccine
o Patients enrolled: 250
Non-Hodgkins Lymphoma
• Phase II
o Drug Class: MAB
o Patients enrolled: 75
Multiple Myeloma
• Phase II/III
o Patients enrolled: 1320
|
